Activated natural killer cells - NantKwest

Drug Profile

Activated natural killer cells - NantKwest

Alternative Names: aNK cells; CST-101; Neukoplast; NK-92 cells; ZRx-101

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator ZelleRx
  • Developer Johann Wolfgang Goethe-Universitat Frankfurt am Main; NantKwest; Rush University; University of Pittsburgh Medical Center; ZelleRx
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I Acute myeloid leukaemia
  • Preclinical Hepatocellular carcinoma; Infections
  • No development reported Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Graft-versus-host disease; Leukaemia; Multiple myeloma; Sarcoma

Most Recent Events

  • 19 Apr 2017 NantCell plans the phase Ib/II QUILT-3.039 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) (NCT03136406)
  • 04 Apr 2017 NantKwest and Viracta Therapeutics enter into a collaboration agreement to investigate combination of activated natural killer cells and VRx 3996 in broad range of cancers
  • 04 Apr 2017 NantKwest plans clinical trials for activated natural killer cells in combination with VRx 3996
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top